Physician profile
Naeem Raza
NPI 1447214994
$73,826.33
in general payments reported to CMS, 2019-2025
27 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,518 · 2020: $1,857 · 2021: $8,334 · 2022: $8,662 · 2023: $18K · 2024: $14K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Food and Beverage: $4,992 · Travel and Lodging: $3,010 · Consulting Fee: $1,110 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,230.00 |
| Food and Beverage | $4,991.93 |
| Travel and Lodging | $3,009.92 |
| Consulting Fee | $1,110.00 |
| Education | $113.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $48,662.93 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $10,307.05 | 2024-2025 | Voquezna |
| Allergan, INC. | $9,948.48 | 2019-2020 | |
| Genzyme Corporation | $1,501.80 | 2022-2025 | |
| Gilead Sciences, INC. | $460.14 | 2019-2024 | |
| Janssen Biotech, INC. | $370.78 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Madrigal Pharmaceuticals | $365.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $343.59 | 2020-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $294.69 | 2020-2024 | Dificid, Zinplava |
| Lumendi LLC | $224.48 | 2025 | |
| Pfizer INC. | $215.64 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $186.44 | 2019-2025 | Entyvio, Eohilia |
| Ferring Pharmaceuticals INC. | $136.35 | 2024 | Rebyota |
| Nestle Healthcare Nutrition INC. | $134.21 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $104.79 | 2022-2025 | Dupixent |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $103.92 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $97.05 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $82.87 | 2025 | Reblozyl |
| Ardelyx, INC. | $53.87 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $52.21 | 2021-2024 | |
| Celltrion USA INC. | $41.71 | 2024 | Vegzelma, Zymfentra |
| Braintree Laboratories, INC. | $35.40 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $29.86 | 2025 | Vowst |
| Organon LLC | $21.16 | 2022 | |
| Ucb, INC. | $19.93 | 2020 | |
| Vivus LLC | $17.67 | 2021 | |
| Sandoz INC. | $13.50 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naeem Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.